Vancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic Analyses

Clostridium difficile (C. difficile) infection is the most common cause of nosocomial infectious diarrhea in adults. The spread of a hypervirulent strain of C. difficile has caused recent outbreaks of C. difficile infection. Metronidazole and vancomycin are the antibiotics of choice to treat C. difficile infection. An assessment was prepared to help guide the choice of therapy for C. difficile infection and to inform reimbursement policies in the Canadian publicly funded health care system.The research objectives were to evaluate the relative clinical effectiveness, the relative cost-effectiveness, and the budget impact of using vancomycin or metronidazole in the management of initial episodes of moderate to severe C. difficile infection in children or in adults. Clinical practice guidelines recommendations were also reviewed.

[1]  Kumanan Wilson,et al.  The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. , 2010, Archives of internal medicine.

[2]  Mark A. Miller,et al.  Lack of Increased Colonization with Vancomycin-Resistant Enterococci during Preferential Use of Vancomycin for Treatment during an Outbreak of Healthcare-Associated Clostridium difficile Infection , 2010, Infection Control & Hospital Epidemiology.

[3]  D R Lairson,et al.  Economic healthcare costs of Clostridium difficile infection: a systematic review. , 2010, The Journal of hospital infection.

[4]  L. Miller,et al.  Dose–Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients , 2010, The American Journal of Gastroenterology.

[5]  E. Kuijper,et al.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  O. Dekkers,et al.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  D. Lieu Oral vancomycin 6-week taper regimen, as treatment for both initial and recurrent disease, reduces relapse of Clostridium difficile infection (CDI) , 2009 .

[8]  D. Gravel Reply to Bayardelle , 2009 .

[9]  Mark H. Wilcox,et al.  Clostridium difficile infection: new developments in epidemiology and pathogenesis , 2009, Nature Reviews Microbiology.

[10]  A. Guyot,et al.  Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. , 2009, The Journal of hospital infection.

[11]  Stuart Johnson Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. , 2009, The Journal of infection.

[12]  D. Gerding,et al.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.

[13]  E. Kuijper,et al.  Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  D. Leffler,et al.  Treatment of Clostridium difficile-associated disease. , 2009, Gastroenterology.

[15]  M. Hu,et al.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. , 2009, Gastroenterology.

[16]  P. Malani,et al.  Clostridium Difficile Infection in the “Oldest” Old: Clinical Outcomes in Patients Aged 80 and Older , 2009, Journal of the American Geriatrics Society.

[17]  J. Sanderson,et al.  The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. , 2009, The Lancet. Infectious diseases.

[18]  L. Johnston,et al.  Hospital infection control strategies for vancomycin-resistant Enterococcus, methicillin-resistant Staphylococcus aureus and Clostridium difficile , 2009, Canadian Medical Association Journal.

[19]  C. Seder,et al.  Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. , 2009, American journal of surgery.

[20]  N. McFadden,et al.  Risk Factors for Mortality Following Emergency Colectomy for Fulminant Clostridium difficile Infection , 2009, Diseases of the colon and rectum.

[21]  Mark Miller,et al.  Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Kelly Karpa,et al.  Is there a future for probiotics in preventing Clostridium difficile-associated disease and treatment of recurrent episodes? , 2009, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[23]  L. Mcfarland Renewed interest in a difficult disease: Clostridium difficile infections – epidemiology and current treatment strategies , 2009, Current opinion in gastroenterology.

[24]  C. Donskey,et al.  Skin and Environmental Contamination With Vancomycin-Resistant Enterococci in Patients Receiving Oral Metronidazole or Oral Vancomycin Treatment for Clostridium difficile–Associated Disease , 2009, Infection Control & Hospital Epidemiology.

[25]  K. Garey,et al.  Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.

[26]  I. Critchley,et al.  New agents for Clostridium difficile-associated disease , 2008, Expert opinion on investigational drugs.

[27]  A. Barkun,et al.  Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection , 2008, Canadian Medical Association Journal.

[28]  J. Caeiro,et al.  New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control , 2008, Current opinion in infectious diseases.

[29]  D. Farver,et al.  New advances in the treatment of Clostridium difficile infection (CDI) , 2008, Therapeutics and clinical risk management.

[30]  P. Gastmeier,et al.  Costs of nosocomial Clostridium difficile-associated diarrhoea. , 2008, The Journal of hospital infection.

[31]  C. Donskey,et al.  Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  T. Louie,et al.  Clostridium difficile Infections in a Canadian Tertiary Care Hospital before and during a Regional Epidemic Associated with the BI/NAP1/027 Strain , 2008, Antimicrobial Agents and Chemotherapy.

[33]  J. Pépin Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  E. Kuipers,et al.  Clostridium difficile infection , 2008, The Lancet.

[35]  S. Chasan-Taber,et al.  Results of a phase Iii trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea , 2008 .

[36]  A. Duffy,et al.  Defining Surgical Therapy for Pseudomembranous Colitis With Toxic Megacolon , 2008, Journal of clinical gastroenterology.

[37]  C. Donskey,et al.  Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile-Associated Disease , 2008, Antimicrobial Agents and Chemotherapy.

[38]  J. Halsey Current and future treatment modalities for Clostridium difficile-associated disease. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[39]  David Moher,et al.  Assessing the Quality of Reports of Systematic Reviews: The QUOROM Statement Compared to Other Tools , 2008 .

[40]  T. Monaghan,et al.  Recent advances in Clostridium difficile-associated disease , 2008, Postgraduate Medical Journal.

[41]  R. Nelson,et al.  Probiotics for treatment of Clostridium difficile-associated colitis in adults. , 2008, The Cochrane database of systematic reviews.

[42]  Carlene A. Muto,et al.  Measures to control and prevent Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  B. Fireman,et al.  Case-Control Study of Antibiotic Use and Subsequent Clostridium difficile–Associated Diarrhea in Hospitalized Patients , 2008, Infection Control & Hospital Epidemiology.

[44]  L. Valiquette,et al.  Outcomes of Clostridium difficile-Associated Disease Treated With Metronidazole or Vancomycin Before and After the Emergence of NAP1/027 , 2007, The American Journal of Gastroenterology.

[45]  G. Raugi,et al.  Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  A. Robicsek,et al.  Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  Mark Nuijten,et al.  Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[48]  B. Jackson,et al.  A Cost Comparison of Metronidazole and Vancomycin in the Treatment of Clostridium Difficile Associated Diarrhea: 417 , 2007 .

[49]  Melinda B Davis,et al.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  M. Olsen,et al.  Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. , 2007, Archives of internal medicine.

[51]  A. Akhtar,et al.  Increasing incidence of clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. , 2007, Journal of the National Medical Association.

[52]  M. Dionne,et al.  A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  Bette Jensen,et al.  A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. , 2006, Archives of internal medicine.

[54]  D. Juurlink,et al.  Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  E. Bouza,et al.  Antimicrobial therapy of Clostridium difficile-associated diarrhea. , 2006, The Medical clinics of North America.

[56]  S. Suissa,et al.  Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy , 2006, Canadian Medical Association Journal.

[57]  L. Mcfarland Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease , 2006, The American Journal of Gastroenterology.

[58]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[59]  L. Eggertson C. difficile may have killed 2000 in Quebec: study , 2005, Canadian Medical Association Journal.

[60]  L. Valiquette,et al.  Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec , 2005, Canadian Medical Association Journal.

[61]  V. Morinville,et al.  Clostridium difficile-associated diarrhea in 200 Canadian children. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[62]  F. Friedenberg,et al.  Clostridium difficile Among Hospitalized Patients Receiving Antibiotics A Case-Control Study , 2005, Infection Control & Hospital Epidemiology.

[63]  J. Brophy,et al.  Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review , 2005, Canadian Medical Association Journal.

[64]  J. Pépin,et al.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  D. Musher,et al.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  G. Wolf-Klein,et al.  Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. , 2005, Journal of the American Medical Directors Association.

[67]  Carlene A. Muto,et al.  A Large Outbreak of Clostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use , 2005, Infection Control & Hospital Epidemiology.

[68]  P. Beck,et al.  Clostridium difficile-associated colitis. , 2004, Canadian family physician Medecin de famille canadien.

[69]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[70]  J. Pépin,et al.  Clostridium difficile infection in hospitals: a brewing storm , 2004, Canadian Medical Association Journal.

[71]  F. Friedenberg,et al.  Factors Associated With Failure of Metronidazole in Clostridium difficile–associated Disease , 2004, Journal of clinical gastroenterology.

[72]  T. Karasawa,et al.  Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. , 2004, Journal of medical microbiology.

[73]  F. Friedenberg,et al.  Predicting failure of metronidazole therapy in patients with Clostridium difficile-associated diarrhea , 2003 .

[74]  A. Glatt,et al.  Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. , 2003 .

[75]  S. Malnick,et al.  Treatment of Clostridium Difficile-Associated Diarrhea , 2002, The Annals of pharmacotherapy.

[76]  Ron Goeree,et al.  Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[77]  Lynne V McFarland,et al.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.

[78]  T. Peláez,et al.  Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin , 2002, Antimicrobial Agents and Chemotherapy.

[79]  Mark A. Miller,et al.  Morbidity, Mortality, and Healthcare Burden of Nosocomial Clostridium Difficile-Associated Diarrhea in Canadian Hospitals , 2002, Infection Control & Hospital Epidemiology.

[80]  F. Barbut,et al.  Epidemiology of Recurrences or Reinfections ofClostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.

[81]  Kearney,et al.  Clostridium difficile‐associated diarrhoea in hospitalised patients , 2000, Journal of clinical pharmacy and therapeutics.

[82]  D. Yadav,et al.  Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation , 1998, American Journal of Gastroenterology.

[83]  N. Black,et al.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.

[84]  B. Wiggs,et al.  Recent trends in diagnosis and treatment of Clostridium difficile in a tertiary care facility. , 1998, American journal of surgery.

[85]  M. Wilcox,et al.  Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection? , 1998, The Journal of hospital infection.

[86]  L. Sutherland,et al.  Review article: treatment of Clostridium difficile infection , 1997, Alimentary pharmacology & therapeutics.

[87]  R. Fekety Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. , 1997, The American journal of gastroenterology.

[88]  C. Surawicz,et al.  Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  M. Wilcox,et al.  Financial burden of hospital-acquired Clostridium difficile infection. , 1996, The Journal of hospital infection.

[90]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[91]  T. Riley Antibiotic-Associated Diarrhoea , 1996, PharmacoEconomics.

[92]  W. Graninger,et al.  Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[93]  M. Wilcox,et al.  Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. , 1995, The Journal of antimicrobial chemotherapy.

[94]  L. Peterson,et al.  Clostridium Difficile-Associated Diarrhea and Colitis , 1995, Infection Control & Hospital Epidemiology.

[95]  A. Vernava,et al.  Patterns and prognosis ofClostridium difficile colitis , 1994, Diseases of the colon and rectum.

[96]  D. Gerding,et al.  Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. , 1994 .

[97]  R. Beart,et al.  Changing epidemiology, diagnosis, and treatment of Clostridium difficile toxin‐associated colitis , 1986, The British journal of surgery.

[98]  J. Bartlett Treatment of Clostridium difficile colitis. , 1985, Gastroenterology.

[99]  J. Welch,et al.  Clostridium difficile colitis in surgical patients. , 1984, American journal of surgery.

[100]  D. Gerding,et al.  PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.

[101]  Allison Himmel,et al.  Management of Clostridium difficile Infection , 2020, Chalk Talks in Internal Medicine.

[102]  Guang-xi Li,et al.  Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .

[103]  L. Mcfarland Update on the changing epidemiology of Clostridium difficile-associated disease , 2008, Nature Clinical Practice Gastroenterology &Hepatology.

[104]  C. Suankratay,et al.  A study of Clostridium difficile-associated disease at King Chulalongkorn Memorial Hospital, Thailand. , 2008, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.